Literature DB >> 25982283

IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG.

S Samanta1, H Sun1, H L Goel1, B Pursell1, C Chang1, A Khan2, D L Greiner3, S Cao4, E Lim4, L D Shultz5, A M Mercurio1.   

Abstract

IMP3 (insulin-like growth factor-2 mRNA binding protein 3) is an oncofetal protein whose expression is prognostic for poor outcome in several cancers. Although IMP3 is expressed preferentially in triple-negative breast cancer (TNBC), its function is poorly understood. We observed that IMP3 expression is significantly higher in tumor initiating than in non-tumor initiating breast cancer cells and we demonstrate that IMP3 contributes to self-renewal and tumor initiation, properties associated with cancer stem cells (CSCs). The mechanism by which IMP3 contributes to this phenotype involves its ability to induce the stem cell factor SOX2. IMP3 does not interact with SOX2 mRNA significantly or regulate SOX2 expression directly. We discovered that IMP3 binds avidly to SNAI2 (SLUG) mRNA and regulates its expression by binding to the 5' UTR. This finding is significant because SLUG has been implicated in breast CSCs and TNBC. Moreover, we show that SOX2 is a transcriptional target of SLUG. These data establish a novel mechanism of breast tumor initiation involving IMP3 and they provide a rationale for its association with aggressive disease and poor outcome.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25982283      PMCID: PMC5784260          DOI: 10.1038/onc.2015.164

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells.

Authors:  Wai Leong Tam; Haihui Lu; Joyce Buikhuisen; Boon Seng Soh; Elgene Lim; Ferenc Reinhardt; Zhenhua Jeremy Wu; Jordan A Krall; Brian Bierie; Wenjun Guo; Xi Chen; Xiaole Shirley Liu; Myles Brown; Bing Lim; Robert A Weinberg
Journal:  Cancer Cell       Date:  2013-09-09       Impact factor: 31.743

3.  Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling.

Authors:  Christine M Fillmore; Piyush B Gupta; Jenny A Rudnick; Silvia Caballero; Patricia J Keller; Eric S Lander; Charlotte Kuperwasser
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

4.  Poised lineage specification in multipotential hematopoietic stem and progenitor cells by the polycomb protein Bmi1.

Authors:  Hideyuki Oguro; Jin Yuan; Hitoshi Ichikawa; Tomokatsu Ikawa; Satoshi Yamazaki; Hiroshi Kawamoto; Hiromitsu Nakauchi; Atsushi Iwama
Journal:  Cell Stem Cell       Date:  2010-03-05       Impact factor: 24.633

5.  The SLUG zinc-finger protein represses E-cadherin in breast cancer.

Authors:  Karen M Hajra; David Y-S Chen; Eric R Fearon
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

6.  Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content.

Authors:  Salvatore Pece; Daniela Tosoni; Stefano Confalonieri; Giovanni Mazzarol; Manuela Vecchi; Simona Ronzoni; Loris Bernard; Giuseppe Viale; Pier Giuseppe Pelicci; Pier Paolo Di Fiore
Journal:  Cell       Date:  2010-01-08       Impact factor: 41.582

7.  IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.

Authors:  Otto Walter; Manju Prasad; Shaolei Lu; Robert M Quinlan; Kathryn L Edmiston; Ashraf Khan
Journal:  Hum Pathol       Date:  2009-08-19       Impact factor: 3.466

8.  IMP3 expression is associated with epithelial-mesenchymal transition in breast cancer.

Authors:  Peng Su; Jing Hu; Hui Zhang; Weiwei Li; Ming Jia; Xiaofang Zhang; Xiaojuan Wu; Hongxia Cheng; Lei Xiang; Gengyin Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

9.  Basic helix-loop-helix proteins can act at the E-box within the serum response element of the c-fos promoter to influence hormone-induced promoter activation in Sertoli cells.

Authors:  J Chaudhary; M K Skinner
Journal:  Mol Endocrinol       Date:  1999-05

10.  IMP3 RNP safe houses prevent miRNA-directed HMGA2 mRNA decay in cancer and development.

Authors:  Lars Jønson; Jan Christiansen; Thomas V O Hansen; Jonas Vikeså; Yohei Yamamoto; Finn C Nielsen
Journal:  Cell Rep       Date:  2014-04-03       Impact factor: 9.423

View more
  29 in total

1.  IGF2 mRNA binding protein 3 (IMP3) mediated regulation of transcriptome and translatome in glioma cells.

Authors:  Shruti Bhargava; Vikas Patil; Riyaz Ahmad Shah; Kumaravel Somasundaram
Journal:  Cancer Biol Ther       Date:  2017-12-19       Impact factor: 4.742

2.  Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach.

Authors:  Tanner M Johanns; Jeffrey P Ward; Christopher A Miller; Courtney Wilson; Dale K Kobayashi; Diane Bender; Yujie Fu; Anton Alexandrov; Elaine R Mardis; Maxim N Artyomov; Robert D Schreiber; Gavin P Dunn
Journal:  Cancer Immunol Res       Date:  2016-10-31       Impact factor: 11.151

Review 3.  Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance.

Authors:  Piyush B Gupta; Ievgenia Pastushenko; Adam Skibinski; Cedric Blanpain; Charlotte Kuperwasser
Journal:  Cell Stem Cell       Date:  2018-12-13       Impact factor: 24.633

4.  The SIRT2 Deacetylase Stabilizes Slug to Control Malignancy of Basal-like Breast Cancer.

Authors:  Wenhui Zhou; Thomas K Ni; Ania Wronski; Benjamin Glass; Adam Skibinski; Andrew Beck; Charlotte Kuperwasser
Journal:  Cell Rep       Date:  2016-10-25       Impact factor: 9.423

Review 5.  The plasticity of mRNA translation during cancer progression and therapy resistance.

Authors:  Lucilla Fabbri; Alina Chakraborty; Caroline Robert; Stéphan Vagner
Journal:  Nat Rev Cancer       Date:  2021-08-02       Impact factor: 60.716

Review 6.  Plasticity of Cancer Stem Cell: Origin and Role in Disease Progression and Therapy Resistance.

Authors:  Plabon Kumar Das; Suja Pillai; Md Abdur Rakib; Jahan Ara Khanam; Vinod Gopalan; Alfred K Y Lam; Farhadul Islam
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

7.  Cancer stem-like cells directly participate in vasculogenic mimicry channels in triple-negative breast cancer.

Authors:  Huizhi Sun; Nan Yao; Siqi Cheng; Linqi Li; Shiqi Liu; Zhao Yang; Guanjie Shang; Danfang Zhang; Zhi Yao
Journal:  Cancer Biol Med       Date:  2019-05       Impact factor: 4.248

Review 8.  The emerging role of RNA N6-methyladenosine methylation in breast cancer.

Authors:  Fangchao Zheng; Feng Du; Jiuda Zhao; Xue Wang; Yiran Si; Peng Jin; Haili Qian; Binghe Xu; Peng Yuan
Journal:  Biomark Res       Date:  2021-05-27

Review 9.  IMPs: an RNA-binding protein family that provides a link between stem cell maintenance in normal development and cancer.

Authors:  Nils Degrauwe; Mario-Luca Suvà; Michalina Janiszewska; Nicolo Riggi; Ivan Stamenkovic
Journal:  Genes Dev       Date:  2016-11-15       Impact factor: 11.361

10.  RNA-binding protein IMP3 is a novel regulator of MEK1/ERK signaling pathway in the progression of colorectal Cancer through the stabilization of MEKK1 mRNA.

Authors:  Meng Zhang; Senlin Zhao; Cong Tan; Yanzi Gu; Xuefeng He; Xiang Du; Dawei Li; Ping Wei
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.